Is FDA control over tobacco a smokescreen?

Article

A bill hit the Senate floor today to give FDA regulatory control over tobacco. Critics argue that money spent enacting the new law would be better spent on smoking cessation.

It appears that FDA will soon have more on its overloaded plate of regulatory responsibilities. The Senate votes today on a bill to give FDA control over tobacco production and sales. Critics--mostly Republicans from tobacco-growing states--contend that the approximately $1 billion it will cost to implement FDA mandates would be better off spent in smoking cessation programs. They may be right, if that's where the money goes.

Sen. Edward Kennedy [D-Mass.] who has long pushed for FDA control over tobacco, stated that passing the bill will save "millions of children from addiction and premature death due to tobacco use." His enthusiasm is well placed, but it is doubtful that passing this bill will have a dramatic effect on tobacco as it relates to lung cancer.

Critics of the bill say that it lacks enough authority to impact the widespread tobacco-addiction problem. They note that the bill precludes FDA's authority to ban any class of tobacco products, to eliminate nicotine, [tobacco's addictive component], or to remove additives that are non-toxic but add to the product's allure among certain target groups.

Supporters see this bill as a milestone equal to the 1998 landmark class action suit in which the tobacco companies' settlement pledged more than $206 billion to help fund anti-smoking campaigns. Creative anti-smoking programs have been shown to work; however, most of those settlement dollars never ended up in smoking cessation programs; states who received the money had other plans for their windfall.

In fact, according to GAO data, only 3.5% of the settlement monies went for anti-tobacco programs.

More than 87% of lung cancer in the US is attributed to smoking. The cancer community has a vested interest in Big Tobacco's deadly profits. There are three well-known anti-smoking tools that we know work: high cigarette taxes, anti-smoking campaigns, and strict smoking bans. For instance, in New York, which has the highest priced cigarettes in the country, high school smoking hit a new low, 13.8% blow the national average.

We know what tools work in smoking cessation; we should make sure that that's where we spend the money and political capital.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content